Mid-period crossings: the quarter's story is things that started during it and are still completing
The model's full reasoning — Q1 2022 call → NOThe question asks whether management's account of the just-reported period is built substantially around real business activity that crossed from not-happening to happening partway through the period or just around its edges, and whether management makes clear that this newly started activity is still completing its climb, so the period's reported numbers averaged the 'before' and 'after' and therefore sit below the level at which the business is already running. Let me examine the transcript for evidence of both halves. First half: THE PERIOD CONTAINED REAL STARTS, NARRATED AS STARTS. Management describes one or more concrete pieces of business that genuinely BEGAN during or immediately around the reported period. Looking at the transcript: - Pfizer launched Neglina (Somatrogon) in Germany and Japan, and Canada and Australia. This triggered $85 million in milestone payments received in Q2 (after the period). The launches happened around the period. - Sema4 completed acquisition of GeneDx on April 29 (after Q1 ended, which is March 31). This is a divestiture, not a start. - ModeX acquisition announced today (May 9) - this is after the period, and it's an acquisition, not yet contributing. - Scarlet Health - launched over a year ago, so not new. - Teladoc relationship - announced today, formal relationship. But is it transacting? It says "Scarlet is now offered by Teladoc Health" - this is a new relationship but seems just announced. - 4Kscore FDA approval in December - before the period. Let me think about what actually started during the period: - Pfizer launched Neglina in Germany and Japan - these launches happened, triggering milestones. But the milestones are received in Q2, not in Q1. The launches themselves - were they in Q1? The transcript says "Pfizer recently launched Neglina in the major markets of Germany and Japan as well as in Canada and Australia." The $85 million milestone payments "we will receive in the second quarter of this year." So the launches happened around the period, but the revenue from milestones is in Q2, not Q1. - The Sema4/GeneDx transaction closed April 29 - after Q1. This is a divestiture. - ModeX acquisition - announced today, after the period. What about the core business? The diagnostics segment revenue declined from $507M to $286M due to decreasing COVID testing. This is an established business declining.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AIN | Albany International Corp. | Q3 2023 | 2023-11-07 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
AFL · Q2 2023 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the Japan Post cancer insurance launch in early April, which began selling the product and drove a 60% sales increase as a major contributor. They describe the activity as real and transacting, with Dan Amos noting the significant contribution from the new product. Yoshizumi confirms gradual increase going forward, and Fred highlights runway for more agents and sales calming down after initial jump, indicating the Q2 numbers reflect partial ramp-up rather than full run-rate.
ESE · Q2 2016 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the real mid-period start of Plastique's contribution (acquired partway through Q2, with two months of performance noted and "early performance consistent with our acquisition forecast"), treated as a key new segment. It also explicitly addresses the incomplete climb, noting that the reported Q 2 numbers lag due to partial contribution and that Q3/Q4 will see fuller periods plus seasonality, with the business already running at a higher level as the ramp continues.
PSX · Q4 2016 → YESThe question is about whether management's account of the just-reported period is built substantially around real business activity that crossed from not-happening to happening partway through the per...YES The transcript shows management centering the Q4 story on the Freeport LPG Export Terminal's real start: commissioning completed smoothly, first commercial cargo shipped mid-December (partial Q4 contribution), with full-quarter costs incurred but only partial revenue, and explicit ramp to near-capacity loading in January onward.